CNSC Practice Questions and Answers Updated 2026

CNSC Practice
Questions and
Answers Updated
2026
InBanBintensiveBcareBsetting,BwhichBofBtheBfollowingBcomplicationsBassociatedBwithBm
alnutritionBisBmostBlikelyBtoBoccurBasBaBresultBofBtheBfailureBtoBbeginBnutritionBsupp
ortBearlyBinBtheBtreatmentBregimen?B-BAnswerIncreasedBserumBlevelsBofBprotein-
boundBdrugs



WhichBofBtheBfollowingBisBtheBinpatientBglycemicBtargetBforBcriticallyBillBpatients?B



1:B80-110Bmg/dL

B2:B140-180Bmg/dL

B3:B181-210Bmg/dL

B4:B211-240Bmg/dLB-BAnswer2:B140-180Bmg/dL



TargetsB<110mg/dLBareBnotBrecommended



UnderBconditionsBofBsepsisBandBstress,BwhichBofBtheBfollowingBmetabolicBalterationsB
areBmostBlikelyBtoBoccur?B



1:BIncreasedBglucoseBproductionBandBincreasedBglucoseBuptake

2:BIncreasedBglucoseBproductionBandBdecreasedBglucoseBuptake

3:BDecreasedBglucoseBproductionBandBdecreasedBglucoseBuptake

,4:BDecreasedBglucoseBproductionBandBincreasedBglucoseBuptakeB-
BAnswer2:BIncreasedBglucoseBproductionBandBdecreasedBglucoseBuptake



StressBhormonesBinduceBinsulinBresistanceBandBhyperglycemiaBisBcommonlyBobservedB
withBnutritionBsupport.BItBisBrecommendedBthatBglucoseBlevelsBbeBadequatelyBcontroll
edBtoBavoidBpolyuriaBandBelectrolyteBdisturbances.



WhichBofBtheBfollowingBimmunomodulatingBnutrientsBmayBbeBharmfulBinBpatientsBwit
hBsevereBsepsis?B



1:BArginine

2:BSelenium

3:BNucleicBacids

4:BOmega-3BfattyBacidsB-BAnswer1:BArginine



NitricBoxideBcanBbeBdetrimentalBbyBleadingBtoBcoagulationBabnormalitiesBandBaltered
BhemodynamicBstatus.BInBthisBcase,BarginineBcouldBbeBconsideredBharmful.BBecauseBo
fBtheseBeffects,BthereBisBstillBmuchBdebateBoverBtheBvalueBofBarginineBinBnutritionBs
upportBforBcriticallyBillBpatients.



WhichBofBtheBfollowingBbestBdescribesBenteralBglutamineBsupplementationBinBtheBcriti
callyBillBpatientBnotBinBmultiBorganBfailure?B



1:BEnteralBglutamineBdecreasesBmortality

2:BEnteralBglutamineBdecreasesBventilatorBdays

3:BEnteralBglutamineBdecreasesBhospitalBlengthBofBstay

4:BEnteralBglutamineBdecreasesBnosocomialBinfectionsB-
BAnswer4:BEnteralBglutamineBdecreasesBnosocomialBinfections

,WhichBofBtheBfollowingBareBcounter-
regulatoryBhormonesBresponsibleBforBtheBhypercatabolismBobservedBinBcriticallyBillBtra
umaBpatients?B



1:BGlycogen,Binsulin,Bnorepinephrine

B2:BGlucagon,Bepinephrine,Bcortisol

B3:BGlycerol,Bserotonin,Bthymoglobulin

B4:BGlycerin,Bleptin,BadenosineB-BAnswer2:BGlucagon,Bepinephrine,Bcortisol



InBpatientsBwithBburns,BprovidingBcaloricBsupportBaboveBenergyBexpenditureBhasBbee
nBfoundBtoB



1:BsignificantlyBdecreaseBhospitalBlengthBofBstay.

2:BimproveBwoundBhealingBandBgraftBsuccess.

3:BdecreaseBfatBaccumulationBandBsteatosis.

4:BhaveBnoBeffectBonBpreservationBofBleanBbodyBmass.B-
BAnswer4:BhaveBnoBeffectBonBpreservationBofBleanBbodyBmass.



AlthoughBpatientsBwithBburnsBhaveBincreasedBneeds,BfeedingBinBexcessBofBenergyBexp
enditureBmayBcauseBhyperglycemia,BhepaticBsteatosis,BandBprolongedBventilatorBdepen
dence.BOneBstudyBofBcriticallyBillBburnBpatientsBshowedBthatBcaloricBdeliveryBbeyondB
1.2BxBmeasuredBrestingBenergyBexpenditureBdidBnotBconserveBleanBbodyBmassBbutBw
asBassociatedBwithBincreasedBfatBmassBaccumulation.



InBpulmonaryBinsufficiency,BexcessiveBcalorieBadministrationBmayBcauseBincreasedBbloo
dBpCO2BresultingBinB



1:BmetabolicBacidosis.

B2:BmetabolicBalkalosis.

B3:BrespiratoryBacidosis.

B4:BrespiratoryBalkalosis.B-BAnswer3:BrespiratoryBacidosis.

, WhichBofBtheBfollowingBisBtrueBofBessentialBfattyBacidBdeficiencyB(EFAD)BinBpatientsB
withBcysticBfibrosisB(CF)?B



1:BRoutineBsupplementationBofBomega-
3BfattyBacidsBisBessentialBinBtheBmanagementBofBCF

2:BEFADBusuallyBdoesBnotBmanifestBinBCFBpatientsBuntilBtheBsecondBdecade.

3:BCFBpatientsBwithoutBpancreaticBinsufficiencyBrarelyBdevelopBEFAD

4:BEFABprofilesBhaveBbeenBshownBtoBimproveBinBCFBpatientsBafterBlungBtransplantatio
nB-
BAnswer4:BEFABprofilesBhaveBbeenBshownBtoBimproveBinBCFBpatientsBafterBlungBtrans
plantation



EFABstatusBisBusuallyBevaluatedBbyBmeasuringBtheBtriene:BtetraeneBratio.BAlthoughBsu
pplementationBwithBomegaB3BfattyBacidsBareBsometimesBusedBinBtheBmanagementBof
BCF,BresultsBfromBclinicalBtrialsBhaveBshownBmixedBresultsBandBfurtherBtrialsBareBnee
dedBtoBdetermineBtheBefficacyBofBroutineBEFABsupplementationBinBtheBmanagementB
ofBCF.



WhichBofBtheBfollowingBisBtheBbestBchoiceBforBfeedingBaBpancreaticBinsufficientBinfan
tBwithBcysticBfibrosis?B




1:BProteinBhydrolysateBformulaBwithBmediumBchainBtriglycerideB(MCT)

B2:BFreeBaminoBacidBformulaBwithBMCT

B3:BHumanBmilk

B4:BStandardBinfantBformulaB-
BAnswerHumanBmilkBisBtheBoptimalBchoiceBoverBstandardBformulaBforBanyBinfantBdue
BtoBmultipleBbeneficialBcomponentsBincludingBimmunologicBproperties,BgrowthBfactors,
BandBbothBpre-
BandBprobiotics.BHumanBmilkBorBstandardBinfantBformulaBwithBappropriateBenzymeBd
osingBisBrecommended.BProteinBhydrolysateBorBfreeBaminoBacidBformulasBcontainingB
MCTBareBnotBindicatedBforBinfantsBwithBcysticBfibrosisB(CF)BunlessBthereBisBanotherB